〔Abstract〕 Objective To observe the clinical efficacy of clopidogrel combined with aspirin in the treatment of myocardial infarction. Methods 68 patients with myocardial infarction admitted to Luoyang Oriental Hospital from April 2018 to April 2020 were selected as the research objects, and the patients were divided into a control group (34 cases: aspirin treatment) and an observation group (34 cases: clopidogrel combined with aspirin treatment), according to different treatment plans. The treatment effects of the two groups of patients were compared. Results The prothrombin time (PT), thrombin time (TT) and activated partial thromboplastin time (APTT) levels of the observation group after 3 courses of treatment were lower than those of the control group, and the difference was statistically significant (P < 0.05) ). The levels of interleukin-6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor-α (TNF-α) in the observation group after 3 courses of treatment were lower than those in the control group, and the difference was statistically significant (P < 0.05). The left ventricular ejection fraction (LVEF) level of the observation group after 3 courses of treatment was higher than that of the control group, and the levels of left ventricular end systolic diameter (LVESD) and left ventricular end diastolic diameter (LVEDD) were lower than those of the control group, the differences were statistically significant (P < 0.05). During the administration period, the incidence of adverse reactions in the observation group (17.65%) was slightly higher than that in the control group (11.76%), but there was no statistically significant difference between the groups (P > 0.05). Conclusion The effect of clopidogrel combined with aspirin in patients with myocardial infarction is significantly better than that of aspirin.